Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BIIB stock price vs CHD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CHD's multiple
Needs CHD P/E.
Implied fair value · at BIIB's multiple
Needs BIIB P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BIOGEN INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
CHURCH & DWIGHT CO., INC. · implied price per share
Bear
$37.82
Base
$45.81
Bull
$56.21
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
BIIB vs PFE
JOHNSON & JOHNSON
BIIB vs JNJ
AMGEN INC
BIIB vs AMGN
ELI LILLY & Co
BIIB vs LLY
Natera, Inc.
BIIB vs NTRA
ILLUMINA, INC.
BIIB vs ILMN
PROCTER & GAMBLE Co
BIIB vs PG
COLGATE PALMOLIVE CO
BIIB vs CL
KIMBERLY CLARK CORP
BIIB vs KMB
ESTEE LAUDER COMPANIES INC
BIIB vs EL
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BIIB's margin advantage and lower leverage will persist without a major re-rating reset, then consider a bullish stance on BIIB because it trades below CHD on every listed valuation multiple while maintaining stronger operating margins and lower leverage.
BIIB trades at a clear valuation discount to CHD on P/E, P/S, EV/EBITDA, and EV/Revenue, suggesting the market is assigning BIIB a lower quality or lower durability profile. The implied price of $287.60 sits well above the current price of $202.95, but the DCF range of $133.03-$179.98 and historical band of $182.66-$223.25 temper the apparent upside.
Supporting Metrics
